Takeda using 'every possible channel' to deliver on Adcetris potential, says Thanos Zomas
As the global medical lead of the Adcetris (brentuximab vedotin) program for Japanese pharma major Takeda (TYO: 4502), Thanos Zomas’ job was made easier by Phase III trial results that he describes as “almost unprecedented.”
The randomized ALCANZA study, initially developed to compare Adcetris to physician’s choice in CD30+ cutaneous T-cell lymphoma (CTCL), delivered highly statistically-significant improvements in terms of sustainability and quality of life.
Results showing a highly statistically-significant improvement in the rate of objective response lasting at least four months were presented almost three years ago, and it was around that time and because of such promising research that Dr Zomas left his role in academia to join Takeda, which partners with Seattle Genetics (Nasdaq: SGEN) on Adcetris.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze